Ori Biotech announces a $9.4M seed round to advance innovation in Cell and Gene Therapy manufacturing
Syndicate includes leading UK investors Amadeus Capital Partners, Delin Ventures and Kindred Capital Appoints Jason C. Foster as Chief Executive Officer
January 8, 2020, London, UK and Philadelphia, USA – Ori Biotech Ltd (Ori), an innovator in Cell and Gene Therapy (CGT) manufacturing, today announced that they successfully closed a $9.4M (£7M) Seed Round which will be used to bring their innovative manufacturing platform to market. The Ori platform will deliver scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers.
